NCT02422264
Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery No drug interventions prevention 4 completed NCT01248884
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) No drug interventions prevention 2 completed NCT02569879
Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia. No drug interventions Not Available Not Available completed NCT01738477
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults No drug interventions prevention 3 completed NCT00316147
Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules No drug interventions prevention 3 completed NCT01294605
Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) No drug interventions prevention 4 completed NCT01277705
Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® No drug interventions prevention 3 completed NCT00964028
Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) No drug interventions prevention 3 completed NCT00635128
Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine No drug interventions prevention 4 completed NCT00544271
Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines. No drug interventions prevention 4 terminated NCT00835237
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine. No drug interventions prevention 3 completed NCT00611559
Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children No drug interventions prevention 4 completed NCT01323959
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults No drug interventions prevention 4 completed NCT00290342
Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants prevention 3 completed NCT00753649
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants No drug interventions prevention 4 completed NCT00871741
Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. No drug interventions prevention 2 terminated NCT00146835
Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine Not Available Not Available completed NCT00320463
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants No drug interventions prevention 3 completed NCT00352963
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). No drug interventions prevention 3 completed NCT00452686
Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine No drug interventions prevention 3 completed NCT01362322
Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents No drug interventions prevention 4 completed NCT01358825
Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ No drug interventions prevention 4 completed NCT01988857
Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children No drug interventions prevention 3 completed NCT00346073
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years No drug interventions prevention 3 completed NCT00879827
Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants No drug interventions prevention 3 completed NCT01568060
Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea No drug interventions Not Available Not Available completed NCT03128489
Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants No drug interventions prevention 3 withdrawn NCT01171989
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose No drug interventions prevention 2 completed NCT00307567
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 No drug interventions prevention 2 completed NCT00610168
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. No drug interventions prevention 4 completed NCT01309646
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine No drug interventions prevention 3 completed NCT00282295
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease prevention 4 completed NCT00385255
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults No drug interventions prevention 3 completed NCT01890850
Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants No drug interventions Not Available Not Available completed NCT01086423
Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine No drug interventions prevention 3 completed NCT00325143
Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine No drug interventions prevention 3 completed NCT01353703
Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine No drug interventions prevention 3 completed NCT00376779
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age No drug interventions prevention 2 completed NCT00263679
Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine. No drug interventions prevention 3 completed NCT00412854
Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib. No drug interventions prevention 3 completed NCT01090453
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants No drug interventions prevention 2 completed NCT00379977
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age No drug interventions prevention 3 completed NCT01457547
Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course No drug interventions prevention 4 completed NCT01453998
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) No drug interventions prevention 2 completed NCT00548171
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 No drug interventions prevention 4 completed NCT02447978
Duration of Protection: GSK DTaP Vaccines No drug interventions Not Available Not Available completed NCT00970307
Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age No drug interventions prevention 2 completed NCT00325156
Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants No drug interventions prevention 4 completed NCT00297856
Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine No drug interventions Not Available Not Available completed NCT00908115
Post Market Surveillance for Infanrix™ No drug interventions Not Available Not Available completed NCT00463437
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines No drug interventions prevention 3 completed NCT01577732
Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers No drug interventions prevention 3 completed NCT00871000
Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. No drug interventions prevention 3 completed NCT01147900
Evaluation of Boostrix™10 Years After Previous Booster Vaccination No drug interventions prevention 4 completed NCT00489970
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 No drug interventions prevention 3 completed NCT01245049
Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children No drug interventions prevention 3 completed NCT00148941
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines prevention 3 completed NCT00871117
Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years No drug interventions prevention 3 completed NCT00627458
Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine No drug interventions prevention 2 completed NCT02096263
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants No drug interventions prevention 3 completed NCT00109330
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine prevention 3 completed NCT01457560
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine No drug interventions prevention 3 completed NCT00406562
Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. No drug interventions prevention 3 completed NCT02853929
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery No drug interventions prevention 4 completed NCT00263692
Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety No drug interventions prevention 2 completed NCT01449812
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine No drug interventions prevention 3 completed NCT00696423
Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children No drug interventions prevention 3 completed